Counts new disease-modifying Alzheimer's therapies approved beyond lecanemab and donanemab. Resolves to the bucket matching the FDA total for 2026. Source: FDA.
Market open
Jun 15, 2026, 03:26 p.m.
Market closes
Jan 8, 2027, 02:26 p.m.
Projected payout
After market closes
